Eli Lilly Doubles Down on in Vivo with $7bn Kelonia Buyout

Why It Matters

The buyout gives Lilly a proprietary lentiviral platform that could lower manufacturing complexity and cost of CAR‑T therapies, accelerating its entry into a market poised for rapid growth. It also diversifies Lilly’s oncology portfolio with a promising multiple‑myeloma candidate, strengthening its competitive position against rivals pursuing in vivo approaches.

Key Takeaways

• Lilly pays up to $7 bn for Kelonia’s in vivo gene‑therapy platform.
• Platform iGPS enables body’s immune cells to produce anti‑BCMA CAR‑Ts.
• Deal adds KLN‑1010 Phase I multiple‑myeloma asset to Lilly’s pipeline.
• Milestone payments of $3.75 bn tied to clinical success of pipeline.
• Acquisition positions Lilly against Orna’s LNP approach in in vivo CAR‑T race.

Pulse Analysis

Lilly’s acquisition of Kelonia marks a decisive move into in vivo gene‑editing, a sector that promises to simplify the costly, patient‑specific manufacturing that has limited the reach of autologous CAR‑T therapies. By securing iGPS, a lentiviral vector system that programs a patient’s own immune cells to express anti‑BCMA CAR‑Ts, Lilly aims to reduce production timelines and expand access to high‑value oncology treatments. The deal also adds KLN‑1010, a single‑dose, BCMA‑directed therapy currently in Phase I, positioning the company to capture market share in multiple‑myeloma, a disease with significant unmet need.

The lentiviral approach championed by Kelonia differs from the lipid‑nanoparticle (LNP) platforms pursued by competitors such as Orna. Lentiviral vectors can achieve stable, long‑term gene expression, potentially delivering deeper and more durable responses. However, safety concerns persist, as high vector doses may trigger immune reactions, a risk highlighted by recent AstraZeneca trial data. LNP systems, while generally better tolerated, often require repeated dosing and may not sustain the same therapeutic intensity. Lilly’s dual‑track strategy—maintaining its Orna LNP assets while adding Kelonia’s lentiviral technology—allows it to hedge bets on the eventual market leader.

From a commercial perspective, the acquisition signals Lilly’s intent to become a dominant player in the next generation of cell and gene therapies. The $3.75 bn milestone structure ties future payouts to regulatory approvals and sales, aligning incentives with successful commercialization. As insurers and health systems scrutinize the high price tags of ex vivo CAR‑Ts, in vivo solutions that lower manufacturing costs could accelerate payer adoption. Analysts expect the in vivo CAR‑T market to expand at double‑digit rates over the next decade, and Lilly’s expanded portfolio positions it to capture a sizable share of that growth.